AnaptysBio (ANAB) Stock Overview
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ANAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.73 |
| 52 Week High | US$68.39 |
| 52 Week Low | US$15.40 |
| Beta | 0.41 |
| 1 Month Change | 3.31% |
| 3 Month Change | 17.02% |
| 1 Year Change | 199.05% |
| 3 Year Change | 166.21% |
| 5 Year Change | 166.84% |
| Change since IPO | 233.71% |
Recent News & Updates
Recent updates
AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement
Nov 13AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up
Jul 16
Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now
Jun 11Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 08Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?
May 07AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Apr 03AnaptysBio: A Shadow Of Its Former Self
Mar 06AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Feb 14AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
Dec 18AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
Nov 21AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet
Nov 07AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
Nov 01AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
Aug 15AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
Jul 08News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Shareholder Returns
| ANAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.2% | 2.3% | -0.3% |
| 1Y | 199.1% | 31.7% | 16.1% |
Return vs Industry: ANAB exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: ANAB exceeded the US Market which returned 16% over the past year.
Price Volatility
| ANAB volatility | |
|---|---|
| ANAB Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ANAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANAB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 104 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| ANAB fundamental statistics | |
|---|---|
| Market cap | US$1.59b |
| Earnings (TTM) | -US$13.23m |
| Revenue (TTM) | US$234.60m |
Is ANAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANAB income statement (TTM) | |
|---|---|
| Revenue | US$234.60m |
| Cost of Revenue | US$135.97m |
| Gross Profit | US$98.63m |
| Other Expenses | US$111.87m |
| Earnings | -US$13.23m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 42.04% |
| Net Profit Margin | -5.64% |
| Debt/Equity Ratio | 743.2% |
How did ANAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 16:33 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AnaptysBio, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Etzer Darout | Barclays |
| Michael King | Citizens JMP Securities, LLC |